Transaction DateRecipientSharesTypePriceValue
Rasna Therapeutics
Rasna Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


Rasna Therapeutics, Inc. develops small molecule drug candidates that focus on treating acute myeloid leukemia. The company was founded in 2013 and is headquartered in New York, NY.


Ticker: RASP
Sector: Commercial Services
Industry: Miscellaneous Commercial Services
SEC Central Index Key (CIK): 1582249
Employees:
Exchange: US OTC
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Common Stock, Shares, Issued: $69 M (0%)